Chemical Tools for Indications Discovery

[1]  Walter Sneader,et al.  Drug Discovery (The History) , 2005 .

[2]  C. Hart,et al.  Finding the target after screening the phenotype. , 2005, Drug discovery today.

[3]  Charles Kung,et al.  Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Randall W King,et al.  Dissecting cell biology with chemical scalpels. , 2005, Current opinion in cell biology.

[5]  A. Hopkins,et al.  Navigating chemical space for biology and medicine , 2004, Nature.

[6]  T. Insel,et al.  NIH Molecular Libraries Initiative , 2004, Science.

[7]  Andrew Hopkins,et al.  Are drugs discovered in the clinic or the laboratory , 2004 .

[8]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[9]  Richard Morphy,et al.  From magic bullets to designed multiple ligands. , 2004, Drug discovery today.

[10]  Michael S Lajiness,et al.  Molecular properties that influence oral drug-like behavior. , 2004, Current opinion in drug discovery & development.

[11]  C. Wermuth.  Selective optimization of side activities: another way for drug discovery. , 2004, Journal of medicinal chemistry.

[12]  B. Andrews,et al.  Old Drugs, New Tricks Using Genetically Sensitized Yeast to Reveal Drug Targets , 2004, Cell.

[13]  J. C. Hinshaw,et al.  Discovering Modes of Action for Therapeutic Compounds Using a Genome-Wide Screen of Yeast Heterozygotes , 2004, Cell.

[14]  G. Superti-Furga,et al.  Rediscovering the sweet spot in drug discovery. , 2003, Drug discovery today.

[15]  B. Shoichet,et al.  Identification and prediction of promiscuous aggregating inhibitors among known drugs. , 2003, Journal of medicinal chemistry.

[16]  B. Stockwell,et al.  Biological mechanism profiling using an annotated compound library. , 2003, Chemistry & biology.

[17]  B. Shoichet,et al.  A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.

[18]  Anthony J Viera,et al.  Off-label applications for SSRIs. , 2003, American family physician.

[19]  J. Lehár,et al.  Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T. Mayer,et al.  Chemical genetics: tailoring tools for cell biology. , 2003, Trends in cell biology.

[21]  I. Muegge.  Selection criteria for drug‐like compounds , 2003, Medicinal research reviews.

[22]  Brian K Shoichet,et al.  Kinase inhibitors: not just for kinases anymore. , 2003, Journal of medicinal chemistry.

[23]  Bernard Ravina,et al.  From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials , 2002, Nature Neuroscience.

[24]  Walters Wp,et al.  Guiding molecules towards drug-likeness. , 2002 .

[25]  J. Proudfoot.  Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. , 2002, Bioorganic & medicinal chemistry letters.

[26]  Esther F. Schmid,et al.  Discovery, innovation and the cyclical nature of the pharmaceutical business. , 2002, Drug discovery today.

[27]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[28]  Alison Abbott,et al.  Neurologists strike gold in drug screen effort , 2002, Nature.

[29]  W Patrick Walters,et al.  Prediction of 'drug-likeness'. , 2002, Advanced drug delivery reviews.

[30]  A. Furlan,et al.  Gabapentin for Neuropathic Pain: Systematic Review of Controlled and Uncontrolled Literature , 2001, The Clinical journal of pain.

[31]  T. Willson,et al.  Chemical genomics: Functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism , 2001, Medicinal research reviews.

[32]  I. Muegge,et al.  Simple selection criteria for drug-like chemical matter. , 2001, Journal of medicinal chemistry.

[33]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[34]  J. Wang,et al.  Toward designing drug-like libraries: a novel computational approach for prediction of drug feasibility of compounds. , 1999, Journal of combinatorial chemistry.

[35]  Ajay,et al.  Recognizing molecules with drug-like properties. , 1999, Current opinion in chemical biology.

[36]  C. Crews,et al.  Chemical genetics: exploring and controlling cellular processes with chemical probes. , 1999, Trends in biochemical sciences.

[37]  R. Spencer,et al.  High-throughput screening of historic collections: observations on file size, biological targets, and file diversity. , 1998, Biotechnology and bioengineering.

[38]  A J Moskowitz,et al.  Capturing the unexpected benefits of medical research. , 1998, The New England journal of medicine.

[39]  S. Schreiber.  Chemical genetics resulting from a passion for synthetic organic chemistry. , 1998, Bioorganic & medicinal chemistry.

[40]  Ajay,et al.  Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.

[41]  Darrell R. Schroeder,et al.  A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation , 1997 .

[42]  T. Blundell.  Structure-based drug design. , 1996, Nature.

[43]  Rosemary Roberts,et al.  FDA Center for Drug Evaluation and Research (CDER) Pediatric Plan and New Regulations , 1996 .

[44]  T. Mitchison,et al.  Towards a pharmacological genetics. , 1994, Chemistry & biology.

[45]  M. Koronkowski,et al.  Finasteride: The First 5α‐Reductase Inhibitor , 1993 .

[46]  I. Kuntz.  Structure-Based Strategies for Drug Design and Discovery , 1992, Science.

[47]  F. Milord,et al.  DIFLUOROMETHYLORNITHINE FOR ARSENO-RESISTANT TRYPANOSOMA BRUCEI GAMBIENSE SLEEPING SICKNESS , 1987, The Lancet.

[48]  S. van Gestel,et al.  Thirty‐three years of drug discovery and research with Dr. Paul Janssen , 1986 .

[49]  Guthrie Dj,et al.  Obituary: Douglas James Guthrie. , 1975 .

[50]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[51]  John P. Overington,et al.  Pleiotropic Effects of Statins , 2004 .

[52]  Andrej Sali,et al.  Comparative Protein Structure Modeling and its Applications to Drug Discovery , 2004 .

[53]  Andrew L Hopkins,et al.  Structural bioinformatics in drug discovery. , 2003, Methods of biochemical analysis.

[54]  D. Moskowitz,et al.  Is angiotensin I-converting enzyme a "master" disease gene? , 2002, Diabetes technology & therapeutics.

[55]  D. Moskowitz,et al.  From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example. , 2002, Diabetes technology & therapeutics.

[56]  C. Pritchard,et al.  Capturing the Unexpected Benefits of Medical Research , 2001 .

[57]  Maria Palmisano,et al.  Human dermal safety studies with eflornithine HCl 13.9% cream (Vaniqa), a novel treatment for excessive facial hair. , 2000 .

[58]  H Kubinyi,et al.  Chance favors the prepared mind--from serendipity to rational drug design. , 1999, Journal of receptor and signal transduction research.

[59]  A. Markham,et al.  Finasteride: a review of its use in male pattern hair loss. , 1999, Drugs.